Skip to main content

Table 1 Incidence of AEs during the AOM 400 maintenance phase

From: Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study

AE, n (%) De novo, n = 379 Rollover, n = 85 Total, N = 464
TEAEs 323 (85.2) 51 (60.0) 374 (80.6)
Serious TEAEs 27 (7.1) 3 (3.5) 30 (6.5)
Nonserious TEAEs 318 (83.9) 49 (57.6) 367 (79.1)
Severe TEAEs 39 (10.3) 2 (2.4) 41 (8.8)
Discontinued AOM 400 due to TEAEs 44 (11.6) 3 (3.5) 47 (10.1)
Discontinued AOM 400 due to AE/death 45 (11.9) 3 (3.5) 48 (10.3)
Deaths 1 (0.3) 0 1 (0.2)
  1. AE adverse event, AOM 400 aripiprazole once-monthly 400 mg, TEAE treatment-emergent AE